ESR1 and breast carcinoma: Elacestrant is the first orally available selective estrogen receptor degrader (SERD) (Orserdu®), developed by Stemline Therapeutics Inc, (New York, NY, USA) Elacestrant received FDA approval in January 2023 for ER-positive, HER2-negative advanced breast cancer with ESR1 mutation [18,19,20].